Nurix Therapeutics
Patents, Design & Utilities

Last updated:

List of all Nurix Therapeutics patents 8 in total

Status Patent
Application
Utility: BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY External link
Filling date: 26 Sep 2025 Issue date: 12 May 2022
Application
Utility: BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF External link
Filling date: 26 Sep 2025 Issue date: 18 Nov 2021
Application
Utility: BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY External link
Filling date: 26 Sep 2025 Issue date: 1 Jul 2021
Application
Utility: CBL INHIBITORS AND COMPOSITIONS FOR USE IN ADOPTIVE CELL THERAPY External link
Filling date: 26 Sep 2025 Issue date: 25 Mar 2021
Application
Utility: CBL INHIBITORS AND COMPOSITIONS FOR EXPANSION OF IMMUNE CELLS External link
Filling date: 26 Sep 2025 Issue date: 25 Mar 2021
Application
Utility: SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF External link
Filling date: 26 Sep 2025 Issue date: 25 Feb 2021
Application
Utility: CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF External link
Filling date: 26 Sep 2025 Issue date: 25 Feb 2021
Application
Utility: 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS External link
Filling date: 26 Sep 2025 Issue date: 15 Oct 2020

Showing 1 to 8 of 8 patents.